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Abstract
Background: Preeclampsia is a dangerous cardiovascular disorder of pregnancy that leads to an increased risk of
future cardiovascular and metabolic disorders. Much of the pathogenesis and mechanisms involved in cardiac
health in preeclampsia are unknown. A novel anti-angiogenic protein, FKBPL, is emerging as having a potential role
in both preeclampsia and cardiovascular disease (CVD). Therefore, in this study we aimed to characterise cardiac
health and FKBPL regulation in the rat reduced uterine perfusion pressure (RUPP) and a 3D cardiac spheroid model
of preeclampsia.
Methods: The RUPP model was induced in pregnant rats and histological analysis performed on the heart, kidney,
liver and placenta (n ≥ 6). Picrosirius red staining was performed to quantify collagen I and III deposition in rat
hearts, placentae and livers as an indicator of fibrosis. RT-qPCR was used to determine changes in Fkbpl, Icam1,
Vcam1, Flt1 and Vegfa mRNA in hearts and/or placentae and ELISA to evaluate cardiac brain natriuretic peptide
(BNP45) and FKBPL secretion. Immunofluorescent staining was also conducted to analyse the expression of cardiac
FKBPL. Cardiac spheroids were generated using human cardiac fibroblasts and human coronary artery endothelial
cells and treated with patient plasma from normotensive controls, early-onset preeclampsia (EOPE) and late-onset
preeclampsia (LOPE); n = 3. FKBPL and CD31 expression was quantified by immunofluorescent labelling.
Results: The RUPP procedure induced significant increases in blood pressure (p < 0.001), collagen deposition (p <
0.001) and cardiac BNP45 (p < 0.05). It also induced a significant increase in cardiac FKBPL mRNA (p < 0.05) and
protein expression (p < 0.01). RUPP placentae also exhibited increased collagen deposition and decreased Flt1
mRNA expression (p < 0.05). RUPP kidneys revealed an increase in average glomerular size (p < 0.05). Cardiac
spheroids showed a significant increase in FKBPL expression when treated with LOPE plasma (p < 0.05) and a trend
towards increased FKBPL expression following treatment with EOPE plasma (p = 0.06).
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Conclusions: The rat RUPP model induced cardiac, renal and placental features reflective of preeclampsia. FKBPL
was increased in the hearts of RUPP rats and cardiac spheroids treated with plasma from women with
preeclampsia, perhaps reflective of restricted angiogenesis and inflammation in this disorder. Elucidation of these
novel FKBPL mechanisms in cardiac health in preeclampsia could be key in preventing future CVD.
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Background
Preeclampsia is a dangerous cardiovascular disorder of
pregnancy that affects around 5-8% of pregnancies and
is one of the leading causes of maternal and foetal mor-
bidity and mortality worldwide [1]. Preeclampsia typic-
ally presents during the second half of pregnancy (> 20
weeks of gestation) and is characterised by the new-
onset of hypertension (> 140/90mmHg) in the presence
of proteinuria (> 300mg/day) or other end-organ dys-
function, often that of the liver and kidneys [2, 3]. While
low-dose aspirin has been investigated as a potential pre-
ventative treatment, the only cure for preeclampsia re-
mains the delivery of the placenta and the baby, which is
often at pre-term [4–6]. In addition to the immediate
complications of a pregnancy affected by preeclampsia,
women and babies affected by this disease are at a
greater risk of developing post-partum cardiovascular,
metabolic and neurological disorders [7–11]. In fact,
women who are diagnosed with early-onset preeclampsia
(EOPE; presenting prior to 34 weeks of gestation) are at
a 9–10-fold increased risk of cardiovascular disease
(CVD)-related deaths, while women diagnosed with late-
onset preeclampsia (LOPE; presenting after 34 weeks
gestation) are at a 2-fold increased risk of CVD-related
death compared to those with normotensive pregnancies
[12, 13]. Recently, several overlapping pathways and sys-
tems were identified between preeclampsia, hypertension
and heart failure with preserved ejection fraction
(HFpEF) including inflammation, angiogenesis, remodel-
ling and haemostasis [14, 15].
Preeclampsia generally presents with two phenotypes:
EOPE and LOPE; although term preeclampsia can also
occur. While the delineation of these two phenotypes is
still under investigation, EOPE often presents with a
more severe disease state likely due to poor placentation
and intrauterine growth restriction while LOPE results
from poor maternal vascular adaptation perhaps due to
underlying vascular dysfunction [16]. Even though the
complex pathogenesis of this disease remains unknown,
inappropriate placental development due to poor inva-
sion and remodelling of maternal uterine vasculature
and inability of the mother’s cardiovascular system to
adapt to pregnancy-induced changes, appear to have
critical roles. These factors result in aberrant angiogen-
esis, oxidative stress and inflammatory responses [17].
Anti-angiogenic factors including soluble fms-like tyro-
sine kinase-1 (sFlt-1) and soluble endoglin (sEng) are
upregulated in preeclampsia and induce their effects by
blocking the angiogenesis-promoting actions of vascular
endothelial growth factor (VEGF) and placental growth
factor (PlGF). Aberrant angiogenesis is also a key mech-
anism in diastolic dysfunction [18] and could perhaps be
one of the lasting factors increasing the risk of CVD in
women following preeclampsia.
A novel anti-angiogenic protein, FK506-binding protein
like (FKBPL), has recently been identified as having pre-
dictive and diagnostic roles in preeclampsia [19] as well as
being a determinant of CVD [20]. FKBPL is a divergent
member of the immunophilin group that shares similar
structure and functions to the FKBP members but lacks
an essential residue in its peptidyl prolyl isomerases
(PPIase) domain preventing its ability to exert this cata-
lytic activity [21]. FKBPL has been demonstrated to have
many functions including regulating glucocorticoid, an-
drogen and oestrogen receptors as well as angiogenesis
and stem cell differentiation [22–26]. It has been demon-
strated that FKBPL induces anti-angiogenic effects by
binding to the cluster of differentiation 44 (CD44) recep-
tor on the surface of cells, regulating Notch or functioning
as an Hsp90 co-chaperone [27, 28]. FKBPL has been re-
cently implicated in endothelial function and key inflam-
matory pathways [19, 26]. While we have shown FKBPL
to be more highly expressed in women with preeclampsia
compared with healthy controls, its relationship and role
in cardiovascular health in preeclampsia is unknown.
Animal models of preeclampsia have been difficult to
establish, primarily due to the fact that preeclampsia can
only be induced in most species other than humans and
the presence of inter-species variations [29]. The most
reliable animal model of preeclampsia is the surgically
induced reduced uterine perfusion pressure (RUPP)
model. This model has been shown to induce hyperten-
sion [30], proteinuria [30], renal dysfunction [30, 31], an
anti-angiogenic state [32], inflammation [33–35], vaso-
constriction [36], oxidative stress [37], cardiac dysfunc-
tion [38] and intrauterine growth restriction (IUGR) [39,
40] like that of preeclampsia in humans. Given the sig-
nificant association between preeclampsia and CVD, a
deeper investigation of the cardiac health in the RUPP
model is required.
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Furthermore, the use of an appropriate 3D cell culture
model to study the effects of secreted placental factors
on cardiac heart cells would enable a deeper understand-
ing of the cardiac effects of preeclampsia. While trad-
itional 2D cell culture methods are limited in their
ability to recapitulate the cellular structure and function
within a tissue, 3D cell culture methods with polymer-
containing extracellular matrix (ECM), provide a 3D cell
architecture allowing interaction in all spatial dimen-
sions both with other cells and their environment. This
allows for fine-tuning of the microenvironment by modi-
fying properties including elasticity, stiffness, conductiv-
ity and porosity [41].
In this study, we demonstrate in the RUPP model of
preeclampsia, the presence of diastolic dysfunction and
cardiac fibrosis in association with increased cardiac
FKBPL levels. We further show that cardiac spheroids
containing cardiac fibroblasts and endothelial cells,
treated with plasma from women with early- or late-
onset preeclampsia, express higher protein levels of
FKBPL reflective of early restricted angiogenesis.
Methods
Experimental animals
All animal experiments were approved by the North-
ern Sydney Local Health District Animal Ethics Com-
mittee at the Kolling Institute Building (Animal Ethics
number: RESP/18/317). Pregnant Sprague-Dawley rats
were fed a standard sterile chow diet and accessed
water ad libitum. At gestational day (GD) 14, rats
were randomised to the RUPP or Sham surgeries,
which were performed as previously described [42,
43]. Briefly, silver clips were applied to the aorta
above the iliac bifurcation (0.203mm ID) and both
the right and left uterine arcades (0.100-mm ID) to
reduce the blood flow to the uterus by ~ 40%. The
sham procedure was performed by making a midline
incision to open the lower abdominal cavity, though
no clips were applied. On GD18, pregnant rats were
anaesthetised with isoflurane (2–5% inhalation), and
placed on a warm pad to maintain a body
temperature of 37 °C before echocardiography was
performed. They were then anaesthetised again in the
afternoon, after 4 h of recovery, for catheter implant-
ation and acute BP measurements. All rats were un-
conscious during BP recording but maintained at a
similar and stable level of light anaesthesia (respira-
tory rates were controlled at similar levels). Rats were
then euthanised immediately after blood pressure re-
cording and post-mortem tissue collection performed.
Blood, urine, organs, placentae and embryos were col-
lected and stored in paraformaldehyde and liquid ni-
trogen. Hearts, placentae and embryos were also
weighed before being processed.
Echocardiography
Cardiac morphology and function were measured by
echocardiography using a VisualSonics Vevo 3100 echo-
cardiography system while rats were anaesthetised and
body temperature maintained on a warm pad. Stroke
volume (μl), cardiac output (mL/min), LV ejection frac-
tion (%), fractional shortening (%), LV mass (mg) and
LV anterior and posterior wall thicknesses at diastole (d)
and systole (s) were measured from short-axis M-mode
images. LV mass corrected (mg) was obtained by ac-
counting for maternal body weight.
Histology
Organs were formalin fixed, processed using Excelsior
AS Tissue Processor (Thermo Fisher Scientific, USA),
embedded in paraffin wax and stored at room
temperature. Tissue sections (10μm) were subjected to
haematoxylin and eosin (H&E) staining to visualise tis-
sue morphology. A virtual slide was generated using a
Zeiss Axioscan microscope and the size of 50 glomeruli
per sample was measured using the polygon tool in Zen
Lite 3.2 software to generate 2-dimensional surface area
measurements. Overall cell number and cell size were
measured in rat H&E stained liver sections using ImageJ.
Picrosirius red staining was also performed to identify
collagen I and III fibres as markers of fibrosis. Quantifi-
cation of collagen deposition was performed using the
colour threshold function of ImageJ.
Immunofluorescent/immunohistochemical staining
Immunofluorescent staining of rat heart tissue was per-
formed by de-waxing slides in xylene followed by rehy-
dration through an ethanol series. Antigen retrieval was
performed by heating in a pressure cooker with sodium
citrate buffer (10 mM trisodium citrate, 0.05% Tween-
20, pH 6.0) for 15 min. The slides were cooled in an ice
bath and washed with distilled water twice. The slides
were washed in PBST (phosphate buffer saline + 0.1%
Tween-20), incubated in blocking buffer (1%BSA in
PBST – PBS with 0.1% Triton-X) for 1 hour at room
temperature and then incubated in a humidity chamber
overnight with rabbit FKBPL polyclonal antibody (Pro-
teintech, UK) diluted at 1:250 in blocking buffer. The
following day, the slides were washed 3 times with PBST
and incubated with donkey anti-rabbit AlexaFlour 488
(Abcam, UK) at 1:500 dilution with DAPI (Thermo
Fisher, USA) in blocking buffer at room temperature in
a humidity chamber. Six images per heart were taken at
40X magnification using an Olympus BX51 fluorescence
microscope. ImageJ was used to calculate the mean
greyscale value of the fluorescent intensity of FKBPL.
Rat liver sections were similarly dewaxed and rehy-
drated as above and stained for F4/80 by immunohisto-
chemistry using a CSAII kit (Agilent, USA) according to
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the manufacturer’s protocols. Rabbit polyclonal F4/80
(Abcam, UK) was used at a 1:200 dilution and nuclei
visualised by haematoxylin staining. A virtual slide was
generated using a Zeiss Axioscan microscope and 3 ran-
dom regions of interest were extracted and analysed by
ImageJ to determine the average number and % area
covered by F4/80 positive cells.
Brain natriuretic peptide 45 enzyme-linked
immunosorbent assay (ELISA)
BNP is released from the cardiac ventricles in response
to diastolic and systolic dysfunction, which places add-
itional stress on the heart walls [44, 45]. Rat cardiac ly-
sates were used to measure BNP 45 concentrations in
rat hearts using BNP 45 Rat ELISA Kit (Abcam, product
#ab108816, UK) as per the manufacturer’s instructions.
Optical density was detected using the Tecan infinite
M200PRO, (Tecan Austria, GmbH) microplate reader.
FKBPL ELISA
Specific FKBPL protein concentrations of rat hearts were
measured by indirect ELISA developed in-house using a
DuoSet® Ancillary Reagent Kit 1 (R&D Systems, USA).
Briefly, PBS-diluted standards (FKBPL fusion protein;
Proteintech, UK) and samples were added to each well
of a 96-well plate (Immulon 1B, Flat bottom Microtiter
plates, 3355). The plate was incubated overnight on a
shaker at 4 °C. The following day, the plate was washed
3 times with 1x wash buffer before blocking buffer was
added and incubated on a shaker for 2 h at room
temperature. The plate was then washed 3 times with
1X wash buffer before primary antibody (Rabbit FKBPL
Polyclonal antibody, Cat No. 10060-1-AP, 0.4 μg/ml in
1% BSA) was added to each well and incubated on a
shaker for 2 h at room temperature. The plate was
washed 3 times before the secondary antibody was ap-
plied (Anti-Rabbit: ab205722, 2 mg/ml, Dnk PAb to Rb
IgG (HRP)), 100ng/ml in 1% BSA) followed by shaking
for 2hr at room temperature. The plate was washed 5
times, and Colour Reagent A and Colour Reagent B
were mixed in 1:1 and added to each well before incu-
bating in the dark for 20 min at room temperature. Fol-
lowing incubation, stop solution was added and the
absorbance measured at 450 nm and 540 nm using a
Tecan infinite M200PRO, (Tecan Austria, GmbH) mi-
croplate reader. The concentration of unknown samples
was calculated based on a Sigmoidal standard curve gen-
erated from the protein standards.
Real-time quantitative reverse transcription polymerase
chain reaction (RT-qPCR)
RT-qPCR was used to analyse mRNA expression of the
genes Fkbpl, intercellular adhesion molecule 1 (Icam1),
vascular cell adhesion protein 1 (Vcam1), fms-like
tyrosine kinase 1 (Flt1, orvascular endothelial growth
factor receptor 1; Vegfr1) and vascular endothelial
growth factor a (Vegfa) in both the heart and/or placen-
tal tissue of the Sham and RUPP rats. RNA was ex-
tracted from the tissue by homogenising tissue sections
with TRIsure reagent (Bioline, AU) and purified accord-
ing to the manufacturer’s protocol. Extracted RNA was
converted to cDNA by reverse transcription using
Tetro cDNA synthesis kit (Bioline, AU) and corre-
sponding primers for Fkbpl, Icam1, Vcam1, Flt1 and
Vegfa (Table 1). Real-time polymerase chain reaction
(RT-PCR) was conducted using the prepared cDNA
using a SensiFAST SYBR No-ROX Kit (Bioline, AU)
according to the manufacturer’s protocol. The results
were normalised to β-actin and transformed according
to the ΔΔCT method.
Generation of cardiac spheroids
Cardiac spheroids were generated by co-culturing hu-
man cardiac fibroblasts (HCFs) with human coronary ar-
tery endothelial cells (HCAECs) in hanging drop
cultures at a ratio of 1:1 similar to the human heart, ac-
cording to our previously established protocol [46].
Briefly, hanging drop cultures were generated using Per-
fecta 3D® 96-well hanging drop plates (3D Biomatrix,
Ann Arbor, MI, USA) [47]. The spheroids were main-
tained with a fresh growth medium every 2 days and
placed in a 37 °C incubator. Treatment of patient plasma
serum was performed after spheroids were formed (3
days) [46]. Spheroids remained in incubation with
plasma for 6 days. Cardiac spheroids were fixed using
1X PBS containing 4% paraformaldehyde, washed in
PBS/0.01% sodium azide (PBSA), permeabilised using
PBSA containing 0.02% Triton X-100, and blocked with
3% BSA in PBSA. Spheroids were incubated with appro-
priate primary (Anti-FKBPL rabbit pAb, Proteintech UK;
Table 1 Nucleotide sequence of primers used in qPCR
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Anti-CD31 mouse mAb, BD Biosciences, USA) and sec-
ondary (Anti-rabbit Donkey Cy3 conjugated, Abcam,
UK; Anti-mouse Donkey Alexa-fluor 647 conjugated,
Thermo Fisher, USA) antibodies, and nuclei were
stained using Hoechst stain. Isotype IgG antibodies were
used as negative controls.
Human plasma samples
Blood samples from women with early-onset (before 34
weeks’ gestation) or late-onset (after 34 weeks’ gestation)
preeclampsia were collected following the diagnosis in
EDTA coated tubes. Blood was centrifuged at 2000 rpm
for 15 min at 4 °C to collect plasma. Preeclampsia was
defined according to the 2013 ACOG guidelines by the
clinicians in participating hospitals [48]. The study was
approved by the local institutional review boards and
written informed consent was obtained from all partici-
pants as per the principles outlined in the Declaration of
Helsinki. The clinical characteristics of women with pre-
eclampsia and normotensive controls are included in
Table 3.
Statistical analysis
Statistical analysis was performed in GraphPad Prism
(v5). For analyses requiring comparison of the Sham and
RUPP groups, an unpaired Student’s t-test was per-
formed with statistically significant results equivalent to
a p value of less than 0.05, where data was normalized
(as per Shapiro-Wilk normality test), otherwise Mann-
Whitney test was used; for n ≤ 4, a Mann-Whitney test
was performed.
Results
RUPP procedure induces altered cardiovascular
physiology in rats
On GD18, the sham and RUPP cohorts of rats were
euthanised and organs collected and weighed. The scales
used to weigh the organs of the first few animals were
later determined to be insensitive and thus the results
presented here are of the later samples (n = 5). At the
end of study, RUPP rat hearts were significantly heavier
than the controls (sham 1.02 ± 0.05 vs RUPP 1.22 ±
0.01, g; n ≥ 4, p = 0.008, Table 2); however, this did not
translate to a significant difference between the wet
heart: body weight ratio of each group (sham 0.30 ± 0.01
vs RUPP 0.32 ± 0.005, n ≥ 4; p = 0.3, Table 2).
To assess whether the RUPP procedure was successful
in inducing preeclampsia and associated cardiovascular
changes in rats, blood pressure was measured on GD18
in both RUPP (n = 7) and sham surgery (n = 8) rats.
Table 2 demonstrates that systolic blood pressure (sham
113 ± 1 vs RUPP 128 ± 2, mmHg; p < 0.001), diastolic
blood pressure (sham 88 ± 2 vs RUPP 104 ± 2, mmHg;
p < 0.001), mean arterial blood pressure (MABP) (sham
Table 2 Maternal cardiac data in reduced uterine perfusion pressure rat model
Sham (n ≥ 6) RUPP (n ≥ 4) p value
Maternal body weight (before surgery), g 338.6 ± 17.5 379.5 ± 4.87 0.084
Maternal heart weight, g 1.02 ± 0.05 1.22 ± 0.01 0.008**
Heart: Body weight, % 0.304 ± 0.01 0.323 ± 0.005 0.303
Embryo resorption (%) 2.38 ± 1.51 11.22 ± 3.06 0.04*
Embryo weight, g 1.68 ± 0.025 1.61 ± 0.02 0.04
Placental weight, g 0.41 ± 0.009 0.39 ± 0.006 0.047
Heart rate, bpm 369.3 ± 4.8 398.8 ± 3.7 0.0006***
Systolic BP, mmHg 112.6 ± 1.3 127.8 ± 1.9 < 0.0001***
Diastolic BP, mmHg 87.6 ± 1.7 104.0 ± 1.8 < 0.0001***
MABP, mmHg 100.9 ± 1.5 116.7 ± 1.7 < 0.0001***
Stroke volume, μl 215.0 ± 4.326 230.0 ± 13.26 0.304
Cardiac output, mL/min 79 ± 3 85 ± 5 0.067
Ejection fraction, % 82 ± 2 78 ± 2 0.233
Fractional shortening, % 52 ± 2 49 ± 2 0.236
Corrected LV mass, mg 600 ± 14 706 ± 68 0.037*
LV anterior wall systolic, mm 2.9 ± 0.12 2.9 ± 0.11 0.672
LV anterior wall diastolic, mm 1.5 ± 0.04 1.8 ± 0.17 0.152
LV posterior wall systolic, mm 2.8 ± 0.14 2.9 ± 0.09 0.303
LV posterior wall diastolic, mm 1.6 ± 0.05 1.6 ± 0.11 0.994
BP, blood pressure; LV, left ventricular, MABP, mean arterial blood pressure; RUPP, reduced uterine perfusion pressure
Unpaired Student’s t-test or Mann-Whitney test depending on data distribution; *p < 0.05, ***p < 0.001
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101 ± 1 vs RUPP 117 ± 2, mmHg; p < 0.001) and heart
rate (sham 369 ± 5 vs RUPP 399 ± 4, bpm; p < 0.001) were
all significantly increased in RUPP rats compared with
sham control rats. We also observed intrauterine growth
restriction (IUGR) measured by significantly reduced em-
bryo weight (p = 0.04), placental weight (p = 0.047) and
higher embryo resorption rate (p = 0.04; Table 2).
To investigate cardiac health in the RUPP model, echo-
cardiography was performed. No statistically significant
differences in stroke volume, cardiac output, ejection frac-
tion or fractional shortening were observed between sham
or RUPP rats (Table 2). The RUPP hearts had significantly
higher corrected LV mass (sham 600 ± 14 vs RUPP 706 ±
68 mg, p = 0.037). No difference in the remaining echo-
cardiography parameters was observed (Table 2).
RUPP induces fibrosis and increased FKBPL expression in
rat hearts
Picrosirius red staining of collagen I/III fibres revealed a
statistically significant increase in collagen deposition in
RUPP hearts compared with controls (Fig. 1a, b), indi-
cating the development of cardiac fibrosis (sham 9.94 ±
0.8 vs RUPP 18.67 ± 0.9, %; n = 6, p < 0.001). Addition-
ally, BNP, a well-established marker of cardiac
hypertrophy and diastolic dysfunction [49], was analysed
by ELISA using the rat heart protein lysates, showing a
statistically significant increase in BNP protein concentra-
tion in RUPP hearts compared with sham controls (sham
4.12 ± 1.6 vs RUPP 11.84 ± 2.1, ng/μl, n = 6, p = 0.01, Fig.
1c).
RT-qPCR showed a significant increase in the mRNA
expression of Fkbpl in RUPP rat hearts (sham 1.14 ±
0.24 vs RUPP 2.57 ± 0.6, fold change, n = 6, p = 0.03,
Fig. 2a). However, there were no statistically significant
differences in the mRNA expression of Flt1 (sham 1.008
± 0.052 vs RUPP 0.8972 ± 0.085, n ≥ 6, p > 0.05, Fig. 2b)
or Vegfa (sham 1.014 ± 0.065 vs RUPP 1.360 ± 0.198, n
≥ 6, p > 0.05, Fig. 2) between the hearts of RUPP and
sham rats. Similarly, no significant differences between
the mRNA expression of Icam1 or Vcam1 in the hearts
of sham or RUPP rats (Additional File 1, Supplementary
Figure 1). Given that FKBPL protein is prone to post-
translational modifications, the difference in mRNA ex-
pression needed to be confirmed at the protein level. In-
direct ELISA revealed a trend towards an increase in
FKBPL protein concentration in RUPP hearts compared
with Sham controls (sham 3123 ± 270.3 vs RUPP 5095 ±
969.2, ng/mg, n ≥ 6, p = 0.059, Fig. 2d). This trend was
Fig. 1 RUPP surgery increases collagen deposition and BNP45 concentration in rat hearts. a, b Paraffin-embedded rat hearts were sectioned at
10μm thickness and stained with picrosirius red to visualise collagen I/III (red) and muscle cell cytoplasm (yellow) in sham and RUPP rats. Scalebar
= 50 μm. Images taken at × 5 using an Axioscan microscope were analysed for percentage area stained red to quantify collagen deposition as an
indicator of cardiac fibrosis. c Rat heart protein isolated by homogenisation with RIPA lysis buffer was quantified by indirect ELISA against known
standards to quantify protein concentration of BNP45. Data points are expressed as mean percentage ± SEM; n ≥ 6, unpaired Student’s t-test; *p
< 0.05, ***p < 0.001
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supported by a statistically significant increase in FKBPL
expression observed between the RUPP heart tissue
compared with controls (sham 1.0 ± 0.1 vs RUPP 1.46 ±
0.1, n = 5, p = 0.018, Fig. 2e, f).
RUPP procedure leads to fibrosis and decreased
Flt1 expression in rat placentae
Picrosirius red staining of collagen fibres I and III re-
vealed a statistically significant increase in collagen de-
position in RUPP placentae, indicating the presence of
some level of placental fibrosis (sham 1.6 ± 0.16 vs
RUPP 2.4 ± 0.35, %, n = 7, p = 0.03; Fig 3a, b).
Similar to the rat hearts, total RNA was isolated and
analysed by RT-qPCR to determine any changes to
mRNA expression levels of Icam1, Vcam1, Flt1 and
Vegfa. As shown in Supplementary Figure 2, there was
no statistically significant difference in expression of
Icam1 or Vcam1 mRNA between the sham or RUPP
groups. There was, however, a decrease in expression of
Flt1 mRNA in RUPP placentae compared with sham
controls (sham 1.016 ± 0.04 vs RUPP 0.85 ± 0.07, fold
change, n = 7, p = 0.048, Fig. 3c). There was no signifi-
cant difference in the Vegfa mRNA levels in placentae
between the Sham and RUPP rats (sham 1.029 ± 0.085
vs RUPP 0.897 ± 0.091, n = 7, p = 0.189, Fig. 3d).
Increased glomerular size is observed in RUPP kidneys
H&E staining of rat kidneys was performed to visual-
ise tissue morphology. The area of 50 glomeruli
within kidney sections was measured per animal using
Zen Lite (v3.2). The mean of these results demon-
strated a significant increase in the overall size of the
glomeruli within the Bowman’s capsules’ of RUPP rats
compared with sham controls (sham 4355 ± 103.5 vs
RUPP 4935 ± 204.6, μm2, n = 7, p = 0.03; Fig. 4).
While the characteristic endothelial swelling was not
observed, this data suggests glomerular endotheliosis
may be present in RUPP rats, which has previously
been observed in an sFlt-1 administration model of
preeclampsia in rats [50].
Fig. 2 RUPP hearts express higher mRNA and protein levels of FKBPL. Total RNA extracted from rat hearts by TRIsure reagent was analysed by RT-
qPCR to determine mRNA expression levels of Fkbpl, Flt1 and Vegfa. Relative mRNA expression of a Fkbpl, b Flt1 and c Vegfa mRNA levels
comparing sham and RUPP hearts normalized to B-actin. Data presented as mean fold change ± SEM; n ≥ 6; Mann-Whitney t-test; *p < 0.05. d
Fkbpl expression was verified at the protein level by enzyme-linked immunosorbent assay (ELISA), concentration calculated against a known
standard and plotted against total mg of protein per sample. Data presented as mean ± SEM; n ≥ 6; unpaired Student’s t-test. e, f Cardiac FKBPL
expression was further analysed by immunofluorescent staining and intensity measured using ImageJ by analysing greyscale value in six × 40
images per animal. Image brightness was adjusted equally for representative images displayed. Data plotted as mean fold change ± SEM; n ≥ 5;
unpaired Student’s t-test; *p < 0.05
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Signs of potential liver inflammation are observed in
RUPP livers
Given preeclampsia often manifests in liver dysfunction,
we performed histological analysis of rat livers. H&E
analysis of rat liver tissue (presented in Supplementary
Figure 3) revealed an increase in the population of small
cells (5–15 μm2) in RUPP rats. To further decipher the
type of immune cells present in the liver, we performed
immunohistochemistry staining for F4/80, a marker of
macrophages, given their key role in maintaining liver
health. Supplementary Figure 3 e–g shows that there
was a trend towards an increased number of macro-
phages in the liver of RUPP rats compared with controls,
though this was not significant. Further characterisation
of these cell populations by immunohistochemistry
would enable their identification and determine whether
this change is indicative of liver inflammation. Picrosir-
ius red staining revealed no significant increase in colla-
gen I or III fibres (Supplementary Figure 4).
Plasma samples from women with preeclampsia lead to
increased FKBPL expression in cardiac spheroids
Human 3D cardiac spheroids were generated by co-
culturing cardiac fibroblasts and endothelial cells to ana-
lyse FKBPL and CD31 protein expression following
treatment with normotensive (healthy), EOPE and LOPE
human plasma samples. Generation of cardiac spheroids
containing only cardiac fibroblasts and endothelial cells
in the absence of myocytes was based on our previous
study, that highlighted the role played by fibroblasts and
their extracellular matrix on endothelial cell network
formation, a critical aspect of modelling mechanisms
regulating new blood vessel formation in vitro [46]. Fol-
lowing incubation in human plasma from women with
EOPE, LOPE and normotensive controls, cardiac spher-
oids were fixed and probed for immunofluorescent visu-
alisation of FKBPL and CD31 proteins (Fig. 5). Semi-
quantitative protein expression was measured by quanti-
fying the immunofluorescent intensity of stained
Fig. 3 RUPP rats have increased collagen deposition and decreased Flt1 mRNA expression in their placentae. a Paraffin-embedded rat placentae
were sectioned at 10μm thickness and stained with picrosirius red to visualise collagen I and III fibres (red) in sham and RUPP hearts. Scalebar =
100μm. b Images of picrosirius red-stained tissue were taken at × 5 using an Axioscan microscope and analysed for percentage of area stained
red to quantify collagen deposition as an indicator of placental fibrosis. Data points are mean ± SEM; n = 7, unpaired Student’s t-test; *p < 0.05.
RNA extracted from rat placentae by TRIsure reagent was analysed by RT-qPCR to determine mRNA expression levels of c Flt1 and d Vegfa. Data
presented as mean fold change ± SEM; n = 7; Mann-Whitney t-test; *p < 0.05
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spheroids. Our analysis demonstrated a trend towards
increased FKBPL expression in EOPE-treated spheroids
compared with normotensive control plasma (control 1.00
± 0.13 vs EOPE 1.43 ± 0.125, n = 3, p = 0.06, Fig. 6a) and
a significant increase in the expression of FKBPL in
LOPE-treated spheroids compared with normotensive
control plasma (control 1.00 ± 0.13 vs LOPE 1.58 ± 0.05;
p = 0.03; Fig. 6a). There was also a trend towards an in-
crease in CD31 expression (used to measure endothelial
cell network formation in cardiac spheroids) in EOPE-
treated spheroids compared with control. However, this
trend was not statistically significant (control 1.00 ± 0.07
vs EOPE 1.34 ± 0.14, n = 3, p = 0.18, Fig. 6b). There was
no significant difference in CD31 protein expression be-
tween LOPE-treated spheroids compared with healthy
control (control 1.00 ± 0.07 vs LOPE 1.05 ± 0.129; p
= 0.95; Fig. 6b) after treatment with patient plasma
samples. No significance was determined between
EOPE- and LOPE-treated cardiac spheroids in terms
of FKBPL or CD31 expression. There was no differ-
ence in age, BMI and parity between the groups
whereas gestational age at sampling was significantly
Fig. 5 Immunofluorescent images of cardiac spheroids treated with plasma samples from healthy control, early-onset and late-onset
preeclampsia patients. Cardiac spheroids were generated in hanging droplets by co-culturing primary human cardiac fibroblast cells (HCFs) and
human coronary artery endothelial cells (HCAECs) in a 1:1 ratio. Following formation of 3D structures, the spheroids were treated with human
plasma samples from women with or without preeclampsia. After plasma treatment, spheroids were fixated and permeabilised prior to labelling
with antibodies (FKBPL, CD31) and fluorescent stain (Hoechst). a Spheroids treated with plasma from normotensive control pregnancies. b
Spheroids treated early-onset preeclampsia (EOPE) patient plasma. c Spheroids treated with late-onset preeclampsia (LOPE) patient plasma
Fig. 4 RUPP rats present with larger glomeruli in rat kidneys. Paraffin-embedded rat kidneys were cut at 10-μm sections and stained with H&E
staining to visualise tissue morphology. a Images of entire tissue sections were taken at × 4, × 10 and × 20 objective using an Axioscan
microscope to produce virtual slides of sham and RUPP kidneys. Scalebar = 20 μm. b Average glomerular area was measured at a × 20
magnification using ZEN Lite 3.2 software. Data plotted as mean ± SEM; n = 7; unpaired Student’s t-test; *p < 0.05
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lower as well as blood pressure in women with pre-
eclampsia (Table 3).
Discussion
In this study, surgically reduced perfusion to the uterus
in pregnant rats resulted in anatomical and physiological
alterations to maternal hearts, placentae and kidneys
with a number of features of preeclampsia being demon-
strated. The cardiovascular dysfunction particularly in
terms of heart health has not been extensively studied in
this model of preeclampsia before [51]. Given the well-
established association between preeclampsia and in-
creased risk of developing future CVD [52], this is an
important aspect in modelling the manifestation of pre-
eclampsia. In fact, recently published results describe the
overlapping mechanisms between preeclampsia and fu-
ture cardiovascular disease with angiogenesis- and
inflammatory-related pathways playing a key role [15].
The RUPP model is one of the most reliable in vivo
models for studying preeclampsia. Although there is
substantial evidence published exploring this model’s
reflection of human features of preeclampsia, we
aimed to confirm the cardiovascular phenotype in
RUPP rats and to determine the regulation of an
emerging anti-angiogenic protein, FKBPL, which also
regulates some key inflammatory pathways [26, 53].
This is the first study that explores the cardiovascular
health in the RUPP model of preeclampsia and the
association of FKBPL in cardiac dysfunction in
preeclampsia.
A significant increase in systolic, diastolic and mean
arterial blood pressure confirmed that the RUPP proced-
ure had been successful and increased heart rate with
LV hypertrophy was evident, as determined by echocar-
diography. This is in line with what was demonstrated
before in the RUPP model [54, 55]. Additionally, signs of
IUGR were observed with a significant decrease in foetal
and placental weight following reduced placental perfu-
sion, as has previously been described [54]. It is difficult
to determine whether this model is more representative
of EOPE or LOPE. LOPE is diagnosed from 34 weeks of
Fig. 6 Expression of FKBPL and CD31 in cardiac spheroids treated with plasma from healthy control, early-onset and late-onset preeclampsia
patients. Cardiac spheroids generated by co-culturing primary human cardiac fibroblast cells (HCFs) and human coronary artery endothelial cells
(HCAECs) were treated with patient plasma from normotensive controls, early-onset preeclampsia and late-onset preeclampsia.
Immunofluorescent expression of a FKBPL and b CD31 in cardiac spheroids was quantified. Data plotted as mean ± SEM; n = 3; ordinary one-way
ANOVA with Tukey’s multiple comparison test; *p < 0.05
Table 3 Clinical characteristics of women with preeclampsia and normotensive controls
Controls (n = 3) EOPE (n = 3) LOPE (n = 3) p values
Age (years) 32 ± 5.6 32 ± 8.4 33 ± 3.1 0.94
BMI (kg/m2) 27 ± 6 31.3 ± 4.6 27.4 ± 1.3 0.47
Gestational age (weeks) 39.3 ± 0.6 31.5 ± 0.9 35.5 ± 1.8 < 0.001
SBP (mmHg) 116.7 ± 5.8 164.3 ± 14 163.3 ± 2.9 < 0.001
DBP (mmHg) 76.7 ± 5.8 112.3 ± 6.8 106.7 ± 5.8 < 0.001
Number of pregnancies 1.7 ± 0.6 2 ± 1.7 1 ± 0 0.53
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure. Statistical analysis
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gestation, it is a less understood phenotype of pre-
eclampsia, and it likely occurs secondary to maternal
microvascular diseases, reflective of underlying vascular
dysfunction. It seems to develop due to maternal inabil-
ity to meet metabolic and cardiovascular demands of the
growing foetus. On the other hand, EOPE is usually di-
agnosed before 34 weeks of gestation and it is associated
with foetal growth restriction as well as inadequate or
incomplete trophoblast invasion of SUAs, often implicat-
ing placenta as the root cause [17]. Our analysis of pla-
cental collagen deposition found RUPP placenta to be
more fibrotic compared with sham controls.
Picrosirius red staining data of RUPP hearts suggests
the presence of cardiac fibrosis compared to sham con-
trols, which is consistent with the preeclampsia pheno-
type and increased risk of CVD including cardiac
fibrosis, later in life [56–58]. These results are also con-
sistent with another study characterising the cardiac ef-
fects of RUPP in rats that showed a significant increase
in collagen I and III fibrotic markers in RUPP hearts
[59], although these effects have been shown to be re-
versed following a RUPP pregnancy [55]. This cardiac
remodelling and fibrosis is likely driven by inflammation,
as shown in published literature [60], and inflammation
is a common feature of both EOPE and LOPE [61]. We
have noted a significant increase in cardiac levels of
BNP, which is indicative of diastolic dysfunction and
cardiac hypertrophy that is supported by other studies’
findings in preeclampsia models [59, 62].
In addition to cardiac fibrosis, FKBPL was significantly
increased at the mRNA level as a result of the RUPP
procedure. However, FKBPL is a chaperone protein and
prone to post-transcriptional modifications so quantifi-
cation of its expression at the protein level is more in-
formative [63]. Therefore, ELISA was performed on rat
heart protein lysates and immunofluorescent staining of
sectioned tissue, which indeed confirmed an overall in-
crease in FKBPL protein levels in RUPP hearts. This is
aligned with the positive correlation observed previously
between FKBPL plasma levels and diastolic dysfunction
or BNP plasma levels in human samples [20]. Recent
studies show that FKBPL regulates inflammatory STAT3
signalling, via CD44 and NFkB, which are both impli-
cated in preeclampsia [26, 53, 64, 65]. This data supports
our hypothesis that FKBPL may be a novel mechan-
ism of cardiovascular damage in preeclampsia. Recent
data from our group has shown that FKBPL is in-
creased as a result of inflammation through TGF-β
stimulation in cardiac fibroblasts [66]. FKBPL is also
increased in plasma and placentae from women with
preeclampsia [19].
Histological analysis of picrosirius red staining in rat
placentae revealed a significant increase in collagen I
and III deposition in RUPP samples, potentially
indicating the presence of placental fibrosis. Placental fi-
brosis has been found to occur in women with pre-
eclampsia compared with normotensive controls [67].
Additional quantification of fibrotic factors including
connective tissue growth factor (CTGF) or fibronectin in
these placentae could aid in determining the level of fi-
brosis. Of note, placental fibrosis is a prominent feature
of preeclamptic placentae and has been shown to be as-
sociated with the activation of stromal fibroblasts via the
TGF-β1 signalling pathway [67]. Reduced angiogenesis
as depicted by decreased Flt1 expression further sup-
ports this finding.
Given that preeclampsia is frequently associated with
altered renal function and histology, RUPP and sham
kidneys were inspected for altered tissue morphology
showing that glomeruli in RUPP samples had a signifi-
cantly larger surface area. While the RUPP model has
not yet been described as displaying glomerular endothe-
liosis, a characteristic feature of preeclampsia [68, 69],
some changes to kidney tissue were previously noted.
While this measurement is limited to 2-dimensional
analysis rather than a 3-dimensional measurement of
each glomerular structure, it does suggest that there may
be early signs of glomerular endotheliosis. Electron mi-
croscopy or glomerular filtration rate would be import-
ant tools to measure this in future experiments.
Moreover, previous studies have demonstrated an in-
crease in proteinuria and a decrease in glomerular filtra-
tion rate following the RUPP procedure, with the latter
lasting up to 8 weeks postpartum [54, 55]. We also ob-
served the signs of liver inflammation; however, this
needs to be characterised further to determine the con-
tent of inflammatory immune cells.
The effects of plasma secretome collected from
women with preeclampsia on FKBPL expression levels
were evaluated in in vitro 3D cardiac spheroid model to
determine its potential role in the human heart. CD31 as
a marker of endothelial cells was used to evaluate a po-
tential correlation between FKBPL expression and endo-
thelial cell network formation within cardiac spheroids.
Our analysis determined that FKBPL expression was ele-
vated in LOPE-treated spheroids when compared with
healthy controls. A similar trend was measured in
EOPE-treated spheroids compared with healthy controls,
while this was not statistically significant. Therefore, it
appears that circulating factors, likely inflammatory, in
maternal plasma during preeclampsia may induce an
overexpression of FKBPL in cardiac fibroblast and/or
endothelial cells. While we did not observe a significant
change in CD31 expression, potentially due to the short
course of our experiments, future studies using our
model for longer times may help to further evaluate the
mechanisms regulating the role of FKBPL on endothelial
cell network formation. We have previously shown that
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cardiac spheroids can model cardiac-specific patho-
physiological conditions in a time-dependent manner.
For instance, cardiac fibrosis is only measurable in car-
diac spheroids after 3 days of treatment with TGF-β1,
while doxorubicin-mediated toxic effects can be detected
after 24 days in culture [46, 70]. While this study reports
the initial response of human heart tissues to
preeclampsia-derived plasma, future studies may help to
further evaluate the underlying mechanisms that regu-
late the effects of preeclamptic plasma on endothelial
cell network formation.
Perspectives and significance
In our RUPP model, cardiac dysfunction including dia-
stolic dysfunction and cardiac fibrosis was observed as a
result of preeclampsia. Furthermore, we demonstrate, for
the first time, that FKBPL is upregulated in the hearts of
RUPP rats and cardiac spheroids treated with plasma from
women with preeclampsia, supporting our hypothesis that
this novel anti-angiogenic mechanism is associated with
cardiovascular dysfunction in preeclampsia.
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Additional file 1: Additional Figure 1. Relative mRNA expression
levels of endothelial dysfunction markers Icam1 and Vcam1 in RUPP
hearts. Total RNA was collected from 30-50mg sections of cryopreserved
rat hearts by a TRIsure reagent protocol. The relative levels of (A) Icam1
and (B) Vcam1 mRNA were quantified by real-time polymerase chain re-
action (RT-PCR) adjusted to β-actin. Data presented as mean fold change
± SEM; n=7; unpaired t-test. Additional Figure 2. Relative mRNA expres-
sion levels of endothelial dysfunction markers Icam1 and Vcam1 in RUPP
placentae. Total RNA was collected from 30-50mg sections of cryopre-
served rat hearts by a TRIsure reagent protocol. The relative levels of (A)
Icam1 and (B) Vcam1 mRNA were quantified by real-time polymerase
chain reaction (RT-PCR) adjusted to β-actin. Data presented as mean fold
change ± SEM; n=7; unpaired t-test. Additional Figure 3. Cell size and
count of RUPP livers and F4/80 quantification by IHC. Formalin-fixed,
paraffin-embedded rat liver tissue was sectioned at 10μm thickness and
stained with H&E to visualise tissue morphology. Images of entire tissue
sections were taken using an Axioscan microscope to produce virtual
slides of Sham and RUPP livers. (A) Number of cells and (B) cell size of
liver tissue were measured and compared. H&E rat livers were further
analysed by ImageJ to detect and count cells with area 5-15μm2 (indi-
cated by arrows) in (C) Sham and RUPP livers. Scale bar = 50μm. (D)
Number of small cells in livers plotted as mean ± SEM, n=7; unpaired stu-
dent’s t-test; *<0.05, **<0.01. (E) Liver sections were further stained by im-
munohistochemistry with F4/80 antibody to detect macrophages. The (F)
number and (G) % Area of F4/80-positive cells were analysed by ImageJ
and plotted as mean ± SEM, n≥6; unpaired student’s t-test. Additional
Figure 4. Degree of fibrosis of RUPP livers as determined by picrosirius
red staining of collagen fibres. FFPE rat livers were sectioned at 10μm
thickness and stained with picrosirius red to reveal collagen I and III fibres
(red) in (A) sham and (B) RUPP hearts. Scalebar = 100μm. Images taken at
5x using an Axioscan microscope were analysed for percentage area
stained red to quantify collagen deposition as an indicator of fibrosis (C).
Data points are mean ± SEM; n=7, unpaired student’s t-test.
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